Loading...
•
Jun 30, 2021
Pacira Q2 2021 Earnings Report
Pacira BioSciences reported preliminary net product sales for July 2021.
Key Takeaways
Pacira BioSciences reported preliminary unaudited net product sales of EXPAREL and iovera° for July 2021, with EXPAREL average daily sales at 117% of July 2020. The company is confident in achieving its five-year goals of top-line growth and operating margins.
Net product sales reached $42.1 million in July 2021.
EXPAREL sales were $40.9 million in July 2021.
iovera° sales were $1.0 million in July 2021.
EXPAREL average daily sales for July 2021 were 117 percent of July 2020.
Revenue by Segment
Forward Guidance
Pacira BioSciences is confident in achieving its five-year goals of top line growth in at least the high teens and operating margins that exceed 50 percent.
Positive Outlook
- Company expects to achieve top line growth in at least the high teens.
- Company expects operating margins that exceed 50 percent.
Challenges Ahead
- Net product sales were negatively impacted by the COVID-19 pandemic in 2020.
- It is still unclear how long it will take the elective surgery market to normalize.
- There is a risk of restrictions on elective procedures recurring due to COVID-19 variant strains or otherwise.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...